Akari Therapeutics AKTX Stock
Akari Therapeutics Price Chart
Akari Therapeutics AKTX Financial and Trading Overview
| Akari Therapeutics stock price | 10.37 USD |
| Previous Close | 10.7 USD |
| Open | 10.53 USD |
| Bid | 8.01 USD x 200 |
| Ask | 12.6 USD x 200 |
| Day's Range | 9.75 - 11.4 USD |
| 52 Week Range | 3.02 - 49.6 USD |
| Volume | 80.62K USD |
| Avg. Volume | 72.19K USD |
| Market Cap | 20.31M USD |
| Beta (5Y Monthly) | 1.387 |
| PE Ratio (TTM) | |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 28.5 USD |
AKTX Valuation Measures
| Enterprise Value | 13.83M USD |
| Trailing P/E | |
| Forward P/E | -0.745 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.9818319 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | N/A |
Trading Information
Akari Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.387 |
| 52-Week Change | -62.74% |
| S&P500 52-Week Change | 20.20% |
| 52 Week High | 49.6 USD |
| 52 Week Low | 3.02 USD |
| 50-Day Moving Average | 9.61 USD |
| 200-Day Moving Average | 10.11 USD |
AKTX Share Statistics
| Avg. Volume (3 month) | 72.19K USD |
| Avg. Daily Volume (10-Days) | 77.71K USD |
| Shares Outstanding | 1.95M |
| Float | 1.27M |
| Short Ratio | 0.95 |
| % Held by Insiders | 15.55% |
| % Held by Institutions | 12.22% |
| Shares Short | 37.66K |
| Short % of Float | 3.37% |
| Short % of Shares Outstanding | 1.92% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:40 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -19.10% |
| Return on Equity (ttm) | -140.090% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | -30960000 USD |
| Diluted EPS (ttm) | 0 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 7.69M USD |
| Total Cash Per Share (mrq) | 3.95 USD |
| Total Debt (mrq) | 693K USD |
| Total Debt/Equity (mrq) | 3.73 USD |
| Current Ratio (mrq) | 0.597 |
| Book Value Per Share (mrq) | 10.623 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -10759000 USD |
| Levered Free Cash Flow (ttm) | -9383250 USD |
Profile of Akari Therapeutics
| Country | United States |
| State | FL |
| City | Tampa |
| Address | 401 East Jackson Street |
| ZIP | 33602 |
| Phone | 929 274 7510 |
| Website | https://www.akaritx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 5 |
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.
Q&A For Akari Therapeutics Stock
What is a current AKTX stock price?
Akari Therapeutics AKTX stock price today per share is 10.37 USD.
How to purchase Akari Therapeutics stock?
You can buy AKTX shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Akari Therapeutics?
The stock symbol or ticker of Akari Therapeutics is AKTX.
Which industry does the Akari Therapeutics company belong to?
The Akari Therapeutics industry is Biotechnology.
How many shares does Akari Therapeutics have in circulation?
The max supply of Akari Therapeutics shares is 1.95M.
What is Akari Therapeutics Price to Earnings Ratio (PE Ratio)?
Akari Therapeutics PE Ratio is now.
What was Akari Therapeutics earnings per share over the trailing 12 months (TTM)?
Akari Therapeutics EPS is 0 USD over the trailing 12 months.
Which sector does the Akari Therapeutics company belong to?
The Akari Therapeutics sector is Healthcare.
Akari Therapeutics AKTX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26099.77 USD — |
-1.03
|
5.81B USD — | 25995.53 USD — | 26260.68 USD — | — - | 5.81B USD — |
|
US Tech Composite Total Return
XCMP
US
|
32218.91 USD — |
-1.03
|
— — | 32090.23 USD — | 32417.54 USD — | — - | — — |
|
US Tech Capital Market Composite
RCMP
US
|
137.24 USD — |
-1.74
|
— — | 136.92 USD — | 138.23 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1346.8 USD — |
+0.49
|
— — | 1335.94 USD — | 1347.07 USD — | — - | — — |
- {{ link.label }} {{link}}
